Albireo Pharma Inc
ALBO
ALBO was delisted on the 2nd of March, 2023.
41 hedge funds and large institutions have $19.3M invested in Albireo Pharma Inc in 2013 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 9 closing their positions.
237% more call options, than puts
Call options by funds: $870K | Put options by funds: $258K
0% more funds holding
Funds holding: 41 → 41 (0)
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
41% less capital invested
Capital invested by funds: $32.9M → $19.3M (-$13.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.25M |
| 2 |
FNYS
First New York Securities
New York
|
+$1.15M |
| 3 |
VAM
Visium Asset Management
New York
|
+$463K |
| 4 |
Renaissance Technologies
New York
|
+$355K |
| 5 |
Two Sigma Investments
New York
|
+$245K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWMDMG
Austin W. Marxe & David M. Greenhouse
New York
|
-$4.99M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$4.2M |
| 3 |
AG
Artal Group
Luxembourg
|
-$916K |
| 4 |
O
OrbiMed
New York
|
-$855K |
| 5 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$760K |
ALBO Hedge Fund Activity: Q4 2013 in Review
41 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q4 2013, worth a combined $19.3M — down 41% from $32.9M a quarter earlier.
Fund positioning in ALBO was balanced in Q4 2013: 9 funds opened new positions, 9 closed out, 9 added to existing stakes and 10 trimmed.
The largest buyer was Millennium Management, adding an estimated $1.25M. The largest seller was Austin W. Marxe & David M. Greenhouse, exiting entirely with an estimated $4.99M sold.
- 41 institutional investors held Albireo Pharma Inc (ALBO) as of Q4 2013, unchanged from Q3 2013.
- Funds reported $19.3M of Albireo Pharma Inc stock for Q4 2013, down 41% quarter-over-quarter.
- 9 funds opened new Albireo Pharma Inc positions in Q4 2013 and 9 closed out, a net change of 0 holders.
- The largest Albireo Pharma Inc buyer in Q4 2013 was Millennium Management, an estimated $1.25M added.
- The largest Albireo Pharma Inc seller in Q4 2013 was Austin W. Marxe & David M. Greenhouse, an estimated $4.99M sold.
Based on aggregated 13F filings for Q4 2013.